A Phase 3 interventional study of SRP-4045 and SRP-4053 in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 76 sites in 24 countries. Open to male participants aged 6 Years to 13 Years. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 2nd largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2016, is one of 7 in phase 3, and was the 8th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 2+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States
Ages 4+ · Men only
Sarepta Therapeutics, Inc. · Sites in United States, Belgium, Germany and 6 more countries
Men only
Sarepta Therapeutics, Inc. · Sites in United States
Men only
By country, each count listing its studies:
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 6 Years to 13 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 7 · Phase 4 1
First in 2009; this study’s year is marked. 1 started in 2016.
This study's enrollment of 228 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 24 across the 25 interventional studies, 400 across the 2 observational. Of the 21 that completed or were terminated, 15 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sarepta Therapeutics, Inc. is the lead sponsor of 52 studies on the registry; 8 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
2 of the studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT07542314Sarepta Therapeutics, Inc.Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate the efficacy of SRP-4045 (casimersen) and SRP-4053 (golodirsen) compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively.
This is a double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of SRP-4045 and SRP-4053. Eligible participants with out-of-frame deletion mutations amenable to exon 45 or 53 skipping will be randomized to receive once weekly intravenous (IV) infusions of 30 milligrams/kilograms (mg/kg) SRP-4045 or 30 mg/kg SRP-4053 respectively (combined-active group) or placebo for up to 96 weeks (the placebo-controlled period of the trial). This will be followed by an open-label extension period in which all participants will receive open-label active treatment for 48 weeks (up to Week 144 of study).
The study will enroll approximately 222 participants. Twice as many participants will be randomized to receive active treatment as will receive placebo (2:1 randomization).
Clinical efficacy will be assessed at regularly scheduled study visits, including functional tests, such as the 6-minute walk test (6MWT). All participants will undergo a muscle biopsy at baseline and a second muscle biopsy either at Week 48 or Week 96.
Safety will be assessed through the collection of adverse events (AEs), laboratory tests, electrocardiograms (ECGs), echocardiograms (ECHOs), vital signs, and physical examinations throughout the study.
Blood samples will be taken periodically throughout the study to assess the pharmacokinetics of both drugs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants amenable to exon 45 skipping will receive SRP-4045 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
Drug: SRP-4045
Participants amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
Drug: SRP-4053
Participants amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
Drug: SRP-4045 · Drug: SRP-4053 · Drug: Placebo
SRP-4045 solution for IV infusion
Also known as: Casimersen, AMONDYS 45
SRP-4053 solution for IV infusion
Also known as: Golodirsen, VYONDYS 53
SRP-4045 or SRP-4053 placebo-matching solution for IV infusion
Change From Baseline in the 4-Step Ascend Velocity at Week 96
Time frame: Baseline, Week 96
Change from Baseline in the Total Distance Walked During 6MWT at Week 96
Time frame: Baseline, Week 96
Change from Baseline in Rise from Floor Velocity at Week 96
Time frame: Baseline, Week 96
Change From Baseline in the 4-Step Ascend Velocity at Week 144
Time frame: Baseline, Week 144
Change From Baseline in Total Distance Walked During the 10-meter walk/run (10-MWR) Velocity
Time frame: Baseline, Week 96
Change From Baseline in the North Star Ambulatory Assessment (NSAA) Total Score at Week 96
The NSAA is a clinician administered scale that rates the participant's performance on various functional activities. During this assessment, participants will be asked to perform 17 different functional activities, including a 10 meter walk/run, rising from a sit to standing, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. Participants will be graded as follows: 2 = achieves goal without any assistance; 1 = modified method but achieves goal independent of physical assistance from another person; and 0 = unable to achieve goal independently. NSAA Total Score ranges from 0 to 34, with a score of 34 implying normal function.
Time frame: Baseline, Week 96
Change from Baseline in Dystrophin Protein Levels Determined by Western Blot at Weeks 48 or 96
Time frame: Baseline, Week 48 or Week 96
Change from Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Weeks 48 or 96
Time frame: Baseline, Week 48 or Week 96
Plan to share: Undecided
Ran from Sep 2016 to primary completion in Nov 2024, 97 months.
Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 97 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Casimersen · Golodirsen
Muscular Dystrophy, Duchenne →